Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Trading 08-06 09:51:40 EDT

0.6750

+0.0173

+2.63%

High0.6980	Low0.6708	Vol3.70K
Open0.6980	D1 Closing0.6577	Amplitude4.14%
Mkt Cap28.27M	Tradable Cap23.59M	Total Shares41.88M
T/O2.51K	T/O Rate0.01%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.675,"timestamp":1786024203075,"preClose":0.6577,"halted":0,"volume":3703,"delay":0,"changeRate":0.02630378592063265,"floatShares":34944200,"shares":41876087,"eps":-1.4419,"marketStatus":"Trading","change":0.0173,"latestTime":"08-06 09:51:40 EDT","open":0.698,"high":0.698,"low":0.6708,"amount":2512.333677,"amplitude":0.041356,"askPrice":0.6799,"askSize":100,"bidPrice":0.6611,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.4419,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786046400000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":0.6577,"preHourTrading":{"tag":"盘前","latestPrice":0.6615,"preClose":0.6577,"latestTime":"09:29 EDT","volume":463,"amount":315.6266833,"timestamp":1786022953816,"change":0.0038,"changeRate":0.005778,"amplitude":0.078455},"postHourTrading":{"tag":"盘后","latestPrice":0.6832,"preClose":0.6577,"latestTime":"19:53 EDT","volume":1158,"amount":767.2592,"timestamp":1785974009307,"change":0.0255,"changeRate":0.038771,"amplitude":0.057777},"volumeRatio":0.327349},"requestUrl":"/m/hq/s/MIRA/wiki","defaultTab":"wiki","newsList":[{"id":"2657636112","title":"Mira Pharma Reports Positive 7-Day Dog Toxicokinetic Study Results for Obesity Drug Candidate SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636112","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636112?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:02","pubTimestamp":1786017749,"startTime":"0","endTime":"0","summary":"Mira Pharma reports positive 7-day dog toxicokinetic study results for obesity drug candidate SKNY-1Mira Pharmaceuticals reported positive results from a 7-day repeated-dose Beagle dog study of SKNY-1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3Ftx0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656946683","title":"MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2656946683","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656946683?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:33","pubTimestamp":1785533612,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. On July 27, 2026, MIRA Pharmaceuticals received notice from Nasdaq that its common s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCLG","BK4007","MIRA","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391125","title":"Mira Pharmaceuticals Risks NASDAQ Delisting After Shares Fall Below $1 Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391125","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391125?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:01","pubTimestamp":1785531668,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals risks Nasdaq delisting after shares fall below $1 bid price requirementMira Pharmaceuticals received a Nasdaq notice for failing to meet the $1 minimum bid price rule after 30 str","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL8blR1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655080351","title":"Mira Pharmaceuticals provides update on MIRA-55, SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2655080351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655080351?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:36","pubTimestamp":1785418597,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced continued advancement of its two preclinical programs, MIRA-55, an investigational oral non-opioid drug candi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-provides-update-on-mira-55-skny-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-provides-update-on-mira-55-skny-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872999","title":"Mira Pharmaceuticals Advances Mira-55 Toward IND-enabling Studies After Completing Exploratory Tox Dosing in Rats, Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872999?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:08","pubTimestamp":1785413331,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogsMira Pharmaceuticals moved two preclinical oral candidates, MIRA-55 for chronic i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL3wHQ9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00B64PRP62.GBP","MIRA","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","BK4588","SG9999014005.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4007","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","BCDF","LU0314104364.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687216","title":"MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687216?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate DevelopmentMIAMI, July  30, 2026  (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASD","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335999/0/en/MIRA-Pharmaceuticals-Progresses-MIRA-55-and-SKNY-1-Toward-IND-Enabling-Studies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","DEA","LU2237443895.HKD","LU2746668974.SGD","LU2237443549.SGD","BK4194","LU2237443622.USD","MIRA","LU2237443465.HKD","LU2237443382.USD","LU0267386448.USD","BK4006","LU0971096721.USD","LU1363072403.SGD","BK4223","LU0149725797.USD","IE00BFXG1179.USD","CMC","IE00BHPRN162.USD","LU0882574139.USD","LU0170899867.USD","IND","LU2746668461.USD","LU2237443978.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655583363","title":"Mira Pharmaceuticals Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655583363","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655583363?lang=en_us&edition=fundamental","pubTime":"2026-07-29 05:01","pubTimestamp":1785272462,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals announces annual shareholder meetingMira Pharmaceuticals will hold its annual shareholder meeting online on Sept. 11, 2026.Shareholders will vote on electing five directors to the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLc0WWtZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650180181","title":"Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2650180181","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650180181?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:33","pubTimestamp":1783686827,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals'  oral formulation of its oral drug candidate MIRA-55 as a non-opioid therapy for chronic inflammatory pain showed \"positive\" results in pre-clinical studies, supporting its continued development, the clinical-stage company said.The objective of the study was to optimize the MIRA-55's oral formulation, the company said. The one used showed \"reproducible distribution into both brain and liver tissue\" following intake, the company added.Shares of Mira were up more than 4% in recent Friday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650874571","title":"Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2650874571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650874571?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:03","pubTimestamp":1783684980,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43B1DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650871921","title":"Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2650871921","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650871921?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:01","pubTimestamp":1783684906,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Announces Release of MIRA-55 Oral Formulation UpdateMira Pharmaceuticals published a press release on July 10, 2026, reporting positive preclinical results for an optimized oral f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDLbRlbMt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649622919","title":"MIRA Reports Positive Preclinical Data for SKNY-1 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2649622919","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649622919?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:29","pubTimestamp":1783344598,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an announcement. On July 6, 2026, MIRA Pharmaceuticals reported positive preclinical results for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-reports-positive-preclinical-data-for-skny-1-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-reports-positive-preclinical-data-for-skny-1-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624780","title":"Mira Pharmaceuticals reports SKNY-1 formulation results","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624780?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:20","pubTimestamp":1783344006,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company’s oral drug...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-reports-skny-1-formulation-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-reports-skny-1-formulation-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624546","title":"Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624546?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:01","pubTimestamp":1783342901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624508","title":"Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624508?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:01","pubTimestamp":1783342901,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380HY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649624318","title":"Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2649624318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649624318?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:00","pubTimestamp":1783342855,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals reports positive preclinical oral formulation results for obesity, addiction drug candidate SKNY-1Mira Pharmaceuticals reported positive preclinical formulation results for SKNY-1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL83NMf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870546","title":"Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870546","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870546?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:03","pubTimestamp":1782389014,"startTime":"0","endTime":"0","summary":"Mira Pharma reports preclinical study showing Mira-55 reduces anxiety-like behavior, differs from THC mechanismMira Pharmaceuticals released new preclinical data on Mira-55, a cannabinoid analog being","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL8BNzYz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745903","title":"Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745903?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:04","pubTimestamp":1781697871,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42O0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644981745","title":"Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2644981745","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644981745?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:02","pubTimestamp":1781697737,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals submitted an FDA Phase 2a trial protocol for Ketamir-2 to treat chemotherapy-induced peripheral neuropathy.Planned randomized, double-blind, placebo-controlled crossover study tests 300 mg, 600 mg doses in patients with persistent moderate-to-severe pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6nD8FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642049098","title":"Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642049098","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642049098?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:01","pubTimestamp":1781038870,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals filed a Form 3 naming Andriy Mushak as chief financial officer in an initial statement of beneficial ownership dated June 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLbdbNSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642437154","title":"MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642437154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642437154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:44","pubTimestamp":1780958645,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an announcement. On June 6, 2026, MIRA Pharmaceuticals, Inc. implemented a leadership change in i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.2185},{"period":"1month","weight":-0.3112},{"period":"3month","weight":-0.3423},{"period":"6month","weight":-0.4519},{"period":"1year","weight":-0.5701},{"period":"ytd","weight":-0.5644}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.076979},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.024441},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.027651},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.020794},{"month":5,"riseRate":0.666667,"avgChangeRate":0.045339},{"month":6,"riseRate":0,"avgChangeRate":-0.14408},{"month":7,"riseRate":0.666667,"avgChangeRate":0.832369},{"month":8,"riseRate":0,"avgChangeRate":-0.140073},{"month":9,"riseRate":0,"avgChangeRate":-0.197508},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10992},{"month":11,"riseRate":0.333333,"avgChangeRate":0.101722},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.266745}],"exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction